½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1444720

³ú ¸ð´ÏÅ͸µ : ½ÃÀå Á¡À¯À² ºÐ¼®, ¾÷°è µ¿Çâ°ú Åë°è, ¼ºÀå ¿¹Ãø(2024-2029³â)

Brain Monitoring - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Mordor Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

³ú ¸ð´ÏÅ͸µ ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 68¾ï ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2029³â±îÁö 92¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖÀ¸¸ç, ¿¹Ãø ±â°£(2024-2029³â) Áß 6.35%ÀÇ CAGR·Î ¼ºÀåÇÕ´Ï´Ù.

³ú ¸ð´ÏÅ͸µ-½ÃÀå

ÁÖ¿ä ÇÏÀ̶óÀÌÆ®

  • COVID-19 Àü¿°º´Àº ³ú ¸ð´ÏÅ͸µ ±â±â ½ÃÀåÀ» Æ÷ÇÔÇÑ ÀÇ·á ½Ã½ºÅÛ¿¡ Å« ¿µÇâÀ» ¹ÌÃƽÀ´Ï´Ù. Àü ¼¼°è ºÀ¼â·Î ÀÎÇØ ½Å°æÇÐÀû °Ë»ç°¡ ¿¬±âµÇ°Å³ª Áß´ÜµÇ¾î °£Áú ȯÀÚÀÇ Ä¡·á Á¢±Ù¼ºÀÌ °¨¼ÒÇÏ°í ÆÄŲ½¼º´ ȯÀÚ¿¡°Ô ºÎÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÃƽÀ´Ï´Ù. ±×·¯³ª ³ú ¸ð´ÏÅ͸µ ¼­ºñ½º°¡ Àç°³µÇ°í COVID-19 °¨¿°ÀÚ°¡ °¨¼ÒÇÔ¿¡ µû¶ó ½ÃÀåÀº Àü¿°º´À¸·Î ÀÎÇÑ Ä§Ã¼¿¡¼­ ȸº¹µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • Àα¸ °í·ÉÈ­, ³ú ¼Õ»ó ¹ß»ý·ü Áõ°¡, ±â±â »ç¿ë ¹× ÈÞ´ë ¿ëÀ̼º µî ¿©·¯ °¡Áö ¿äÀÎÀÌ ½ÃÀå ¼ºÀåÀ» ÁÖµµÇÏ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 65¼¼ ÀÌ»ó ¹Ì±¹ÀÎ Àα¸´Â 2021³â 5800¸¸ ¸í¿¡¼­ 2050³â±îÁö 8800¸¸ ¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿µÇâÀ» ¹Þ´Â Àα¸ÀÇ ¾à 73%°¡ 75¼¼ ÀÌ»óÀÌ µÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÚÆóÁõ°ú °°Àº ½Å°æÁúȯÀº Àü ¼¼°è¿¡¼­ ¸¸¿¬ÇØ ÀÖÀ¸¸ç, ¼¼°èº¸°Ç±â±¸(WHO)´Â Àü ¼¼°è ¾î¸°ÀÌ 100¸í Áß 1¸íÀÌ ÀÚÆóÁõÀ» ¾Î°í ÀÖ´Ù°í ¿¹ÃøÇß½À´Ï´Ù. µû¶ó¼­ ³ú ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ³ú ¸ð´ÏÅ͸µ ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • Á¦Ç° Ãâ½Ã, ÇÕº´, Àμö µîÀÇ Àü·«Àû È°µ¿µµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î NeuroWave Systems Inc.´Â ÀÓ»ó ÇöÀå¿¡¼­ ¸¶Ãë ¹× ÁøÁ¤ÀÇ ÀûÀý¼ºÀ» Æò°¡Çϱâ À§ÇÑ ³ú ±â´É ¸ð´ÏÅÍÀÎ NeuroSENSE NS-901 ¸ð´ÏÅÍ¿¡ ´ëÇØ ¹Ì±¹ ½ÄÇ°ÀǾ౹(FDA)ÀÇ ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. ºê·¹ÀλçÀ̾ðƼÇÈÀº ÀÏ»óÀûÀÎ ÀÓ»ó ¹× ¿¬±¸ ȯ°æ¿¡¼­ ½Å¼ÓÇÑ ³úÆĸ¦ ¾ò±â À§ÇØ »ç¿ëµÇ´Â °í±Þ ³úÆÄ °Ë»ç(EEG) Àü±Ø ¾î·¹ÀÌÀÎ Â÷¼¼´ë NeuroCap EEG Çìµå¼Â¿¡ ´ëÇÑ FDA ½ÂÀÎÀ» ȹµæÇß½À´Ï´Ù.
  • ÀÌ·¯ÇÑ ¿äÀο¡µµ ºÒ±¸ÇÏ°í, ±â±â ½ÂÀο¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦¿Í ¼÷·ÃµÈ Àü¹®°¡ ºÎÁ·Àº ½ÃÀå ¼ºÀåÀ» ¾ïÁ¦ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Àü¹ÝÀûÀ¸·Î ³ú ¸ð´ÏÅ͸µ Àåºñ ½ÃÀåÀº ³ú ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í Á¦Ç° Ãâ½Ã·Î ÀÎÇØ ¿¹Ãø ±â°£ Áß »ó´çÇÑ ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

³ú ¸ð´ÏÅ͸µ ½ÃÀå µ¿Çâ

³úÆÄ°è´Â ¿¹Ãø ±â°£ Áß °ÇÀüÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

  • ³úÆÄ °Ë»ç(EEG) Àåºñ´Â »ç¶÷ÀÇ µÎÇÇ¿¡ Àü±ØÀ» ¹èÄ¡ÇÏ¿© ³úÀÇ Àü±âÀû È°µ¿À» Æ÷ÂøÇÏ´Â ÀåºñÀÔ´Ï´Ù. ÀÌ Àü±ØÀº ³úÆÄ ÆÐÅÏÀ» ±â·ÏÇÏ¿© ºÐ¼®À» À§ÇØ ÄÄÇ»ÅÍ ¶Ç´Â Ŭ¶ó¿ìµå ¼­¹ö·Î Àü¼ÛÇÕ´Ï´Ù. ÁßȯÀÚ½Ç(ICU)¿¡¼­´Â ÁßȯÀÚÀÇ ³ú È°µ¿À» ½Ç½Ã°£À¸·Î ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖÀ¸¹Ç·Î ³úÆÄ°èÀÇ »ç¿ëÀÌ Á¡Á¡ ´õ Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù. ÁßȯÀڽǿ¡¼­ ³úÆÄ °Ë»ç¸¦ ÇÏ´Â ÁÖ¿ä ÀÌÀ¯´Â ±Þ¼º ³ú¼Õ»óÀÌ Àִ ȯÀÚ¿Í ±×·¸Áö ¾ÊÀº ȯÀÚÀÇ ¹ßÀÛÀ» °¨ÁöÇϱâ À§Çؼ­ÀÔ´Ï´Ù.
  • ³ú Áúȯ Áõ°¡¿Í ³ú ¹®Á¦¸¦ °¨ÁöÇϱâ À§ÇØ ´Ù¾çÇÑ Áö¿ª¿¡¼­ ³úÆÄ ÀåºñÀÇ Ã¤Åà Áõ°¡¿Í °°Àº ¿äÀÎÀÌ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î ±¹¸³º¸°Ç¿øÀÌ 2022³â 7¿ù ¹Ì±¹ º´¿øÀ» ´ë»óÀ¸·Î ½Ç½ÃÇÑ Á¶»ç¿¡ µû¸£¸é ³úÆÄ Àåºñ¸¦ »ç¿ëÇϸé ÀÇ»çÀÇ Àü±âÀû ¹ßÀÛ Áø´ÜÀÌ Å©°Ô °³¼±µÈ °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ÀÓ»ó Áø´Ü°ú ºñ±³ÇßÀ» ¶§ Àü±â »çÁø ¹ßÀÛ Áø´ÜÀÇ ¹Î°¨µµ´Â 77.8¿¡¼­ 100%·Î, ƯÀ̵µ´Â 63.9¿¡¼­ 89%·Î Çâ»óµÇ¾ú½À´Ï´Ù. ÀÌ´Â ¹ßÀÛÀÇ Á¤È®ÇÑ Áø´Ü¿¡ ÀÖÀ¸¸ç, ³úÆÄÀÇ Á߿伺°ú ÁßȯÀڽǿ¡¼­ ³úÆÄÀÇ ³ôÀº äÅ÷üÀ» °­Á¶Çϸç ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ°í ÀÖ½À´Ï´Ù.
  • ¶ÇÇÑ EEG ÀåºñÀÇ ¹ßÀüÀº ÀÌ·¯ÇÑ Àåºñ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ Å©°Ô ±â¿©ÇÏ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 3¿ù À̽º¶ó¿¤¿¡ º»»ç¸¦ µÐ ±â¾÷ Brain.space´Â ±âÁ¸º¸´Ù ´õ ³ªÀº ÃøÁ¤°ªÀ» Á¦°øÇÏ°í Àü¹®°¡ÀÇ µµ¿ò ¾øÀ̵µ ¼³Á¤ÇÒ ¼ö ÀÖ´Â ¹«¼± EEG Àåºñ¸¦ °³¹ßÇß½À´Ï´Ù. ÀÌ ÀåºñÀÇ ºñ¿ë È¿À²¼º°ú »ç¿ë ÆíÀǼºÀº ÇâÈÄ ¼ö³â°£ Å« °ü½ÉÀ» ²ø °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ¶ÇÇÑ 2021³â 5¿ù, Inspira HealthÀÇ ÀϺÎÀÎ Inspira Medical Centers Mullica Hill°ú Vineland´Â Ceribell Rapid Response EEG ¸ð´ÏÅ͸µ Àåºñ¸¦ Ãâ½ÃÇß½À´Ï´Ù. ÀÌ È¹±âÀûÀÎ ±â¼úÀº ÁßÁõ ȯÀÚÀÇ ºñ°æ·Ã¼º ¹ßÀÛ È°µ¿À» ½Äº°ÇÏ°í Áø´ÜÇÏ´Â µ¥ µµ¿òÀ̵Ǹç ÁßÁõ ȯÀÚ°¡ °¡´ÉÇÑ ÇÑ »¡¸® ÃÖ»óÀÇ Ä¡·á¸¦¹ÞÀ» ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.
  • µû¶ó¼­ EEG ±â±â äÅà Áõ°¡¿Í Á¦Ç° Ãâ½Ã Áõ°¡·Î ÀÎÇØ EEG ±â°è ºÎ¹®Àº ¿¹Ãø ±â°£ Áß »ó´çÇÑ ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÏ¹Ì´Â ¿¹Ãø ±â°£ Áß »ó´çÇÑ ½ÃÀå Á¡À¯À²À» À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»ó

  • ºÏ¹Ì´Â ¸î °¡Áö ¿äÀÎÀ¸·Î ÀÎÇØ ³ú ¸ð´ÏÅ͸µ Àåºñ ½ÃÀå¿¡¼­ Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ªÀº ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀÎ Àß ±¸ÃàµÈ ÀÇ·á ÀÎÇÁ¶ó, ÀÇ·á ÁöÃâ Áõ°¡, °í·ÉÈ­ Àα¸ Áõ°¡ÀÇ ÇýÅÃÀ» ´©¸®°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ±â¾÷ÀÇ Áö¼ÓÀûÀÎ Á¦Ç° Ãâ½Ã¿Í ÀÌ Áö¿ªÀÇ ³ôÀº ³ú ¼Õ»ó ¹ß»ý·üÀº ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ¿¹¸¦ µé¾î 2021³â3¿ù¿¡ ¹ßÇ¥µÈ ¹Ì±¹ ³ú ¼Õ»ó ÇùȸÀÇ º¸°í¼­¿¡ µû¸£¸é ¸Å³â ¾à 350 ¸¸ ¸íÀÇ ¹Ì±¹ÀÎÀÌ ¿Ü»ó¼º ³ú ¼Õ»óÀ¸·Î °íÅë ¹Þ°í ÀÖ½À´Ï´Ù. ÀÌ º¸°í¼­´Â ¶ÇÇѺ¸°íµÈ ÃÑ ºÎ»ó °Ç¼ö Áß ¾à 280 ¸¸ °ÇÀÌ ÀÔ¿øÀ» µ¿¹ÝÇÏ°í 60 ¸í Áß 1 ¸íÀº ¿Ü»ó¼º ³ú ¼Õ»ó°ú °ü·ÃµÈ Àå¾Ö¸¦ ¾Î°í ÀÖ´Ù°í ¹àÇû½À´Ï´Ù. ³ú ¸ð´ÏÅ͸µ Àåºñ´Â ¿Ü»ó¼º ³ú¼Õ»óÀÇ Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µ°ú Ä¡·á¿¡ ÇʼöÀûÀ̱⠶§¹®¿¡ ÀÌ·¯ÇÑ ¼Õ»ó ¹ß»ý·ü Áõ°¡´Â ÀÌ·¯ÇÑ Àåºñ¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ¶ÇÇÑ À¯¸®ÇÑ »óȯ Á¤Ã¥, ¸ð¹ÙÀÏ ³úÆÄ ±â°è °³¹ß, ½Ç½Ã°£ ¸ð´ÏÅ͸µ ¹× °æ°í¿Í °°Àº ±â¼ú ¹ßÀüµµ ÀÌ Áö¿ª ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÏ°í ÀÖ½À´Ï´Ù. 2022³â 5¿ù, Philips´Â »õ·Î¿î MR 7700 3.0T MR ½Ã½ºÅÛ¿¡ ´ëÇØ FDA·ÎºÎÅÍ 510(k) ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. À̸¦ ÅëÇØ ¿µ»óÀÇÇаú Àü¹®ÀÇ´Â ÇغÎÇÐÀû ±¸Á¶¿¡ °ÉÃÄ ÀÓ»óÀûÀ¸·Î °ü·ÃµÈ 6°³ÀÇ ¼­·Î ´Ù¸¥ ÇÙÀ» ȹµæÇÒ ¼ö ÀÖ°Ô µË´Ï´Ù.
  • ¶ÇÇÑ Å¬¸®ºí·£µå Ŭ¸®´ÐÀº 2022³â 1¿ù, Áõ»óÀÌ ³ªÅ¸³ª±â Àü¿¡ ½Å°æ ÁúȯÀ» Áø´ÜÇÏ°í ¿¹¹æÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÏ´Â ³ú ¿¬±¸¸¦ ½ÃÀÛÇß½À´Ï´Ù. ÀÌ »õ·Î¿î ¿¬±¸´Â 20³â°£ ½Å°æÇÐÀûÀ¸·Î °Ç°­ÇÑ ÃÖ´ë 200,000¸íÀÇ µ¥ÀÌÅ͸¦ ¼öÁýÇÏ¿© ³ú ÁúȯÀÇ ¹ÙÀÌ¿À¸¶Ä¿¿Í ½Å°æ Àå¾ÖÀÇ ¿¹¹æ ¹× Ä¡·á Ç¥ÀûÀ» ½Äº°Çϱâ À§ÇØ ÁøÇàµÇ¾ú½À´Ï´Ù.
  • ¿ä¾àÇϸé, ³ú Áúȯ Áõ°¡¿Í Áö¼ÓÀûÀÎ ½ÅÁ¦Ç° Ãâ½ÃÀÇ Á¶ÇÕÀº ¿¹Ãø ±â°£ Áß ºÏ¹Ì ³ú ¸ð´ÏÅ͸µ Àåºñ ½ÃÀåÀÇ »ó´çÇÑ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

µÎ³ú ¸ð´ÏÅ͸µ »ê¾÷ °³¿ä

³ú ¸ð´ÏÅ͸µ ½ÃÀåÀº Àû´çÇÑ °æÀïÀÌ ÀÖÀ¸¸ç ¿©·¯ ´ë±â¾÷°ú ¼Ò±Ô¸ð ¾÷°è ±â¾÷À¸·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù. ÇöÀç ¼Ò¼öÀÇ ´ë±â¾÷ÀÌ Æ¯Á¤ ºÎ¹®¿¡¼­ ½ÃÀåÀ» µ¶Á¡ÇÏ°í ÀÖ½À´Ï´Ù. ±×·¯³ª Áß°ß ¹× Áß¼Ò±â¾÷Àº »ç¿ë ÆíÀǼºÀ» Çâ»ó½ÃÅ°´Â »õ·Î¿î ±â¼úÀ» µµÀÔÇÏ°í ±â¼ú ¹ßÀü°ú Á¦Ç° Çõ½ÅÀ» È°¿ëÇÏ¿© ½ÃÀå¿¡¼­ÀÇ ÀÔÁö¸¦ °­È­ÇÏ°í ÀÖ½À´Ï´Ù.

Medtronic PLC, Integra LifeSciences Corporation, Nihon Kohden Corporation, Masimo Corporation, Natus Medical Incorporated µîÀº ³ú ¸ð´ÏÅ͸µ ½ÃÀå¿¡¼­ »ó´çÇÑ ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÏ°í ÀÖ´Â ±â¾÷ÀÔ´Ï´Ù. ±â¾÷ÀÔ´Ï´Ù.

±âŸ ÇýÅÃ

  • ¿¢¼¿ Çü½ÄÀÇ ½ÃÀå ¿¹Ãø(ME) ½ÃÆ®
  • 3°³¿ù°£ÀÇ ¾Ö³Î¸®½ºÆ® Áö¿ø

¸ñÂ÷

Á¦1Àå ¼­·Ð

  • Á¶»çÀÇ ÀüÁ¦Á¶°Ç°ú ½ÃÀåÀÇ Á¤ÀÇ
  • Á¶»ç ¹üÀ§

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå ¿ªÇÐ

  • ½ÃÀå °³¿ä
  • ½ÃÀå ÃËÁø¿äÀÎ
    • °í·ÉÀÚ Àα¸ÀÇ Áõ°¡
    • ³úÀå¾ÖÀÇ ¹ß»ý·ü Áõ°¡
    • ³ú ¸ð´ÏÅ͸µ ±â±âÀÇ ±â¼ú Áøº¸
  • ½ÃÀå ¾ïÁ¦¿äÀÎ
    • ±â±â ½ÂÀο¡ °üÇÑ ¾ö°ÝÇÑ ±ÔÁ¦
    • ±â±â¸¦ Ãë±ÞÇÏ´Â ¼÷·Ã ÀÎÀçÀÇ ºÎÁ·
  • Porter's Five Forces ºÐ¼®
    • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
    • ±¸¸ÅÀÚÀÇ ±³¼··Â
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ´ëüǰ ¹× ¼­ºñ½ºÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀïÀÇ °­µµ

Á¦5Àå ½ÃÀå ¼¼ºÐÈ­

  • Á¦Ç° À¯Çüº°
    • ³úÀÚ°è
    • ³úÆÄ°è
    • ³ú»ê¼Ò ³óµµ°è
    • ±â´ÉÀû ÀÚ±â°ø¸í¿µ»ó¹ý(fMRI)
    • µÎ°³³»¾Ð ¸ð´ÏÅ͸µ ±â±â
    • ±âŸ Á¦Ç° À¯Çü
  • ¿ëµµº°
    • ÆÄŲ½¼º´
    • ¿Ü»ó¼º ³ú¼Õ»ó
    • °£Áú
    • Ä¡¸Å
    • ¼ö¸éÀå¾Ö
    • ±âŸ ¿ëµµ
  • ÃÖÁ¾»ç¿ëÀÚº°
    • º´¿ø
    • Áø´Ü ¼¾ÅÍ
  • Áö¿ª
    • ºÏ¹Ì
      • ¹Ì±¹
      • ij³ª´Ù
      • ¸ß½ÃÄÚ
    • À¯·´
      • µ¶ÀÏ
      • ¿µ±¹
      • ÇÁ¶û½º
      • ÀÌÅ»¸®¾Æ
      • ½ºÆäÀÎ
      • ±âŸ À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
      • Áß±¹
      • ÀϺ»
      • Àεµ
      • È£ÁÖ
      • Çѱ¹
      • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
      • GCC
      • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
      • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¹Ì
      • ºê¶óÁú
      • ¾Æ¸£ÇîƼ³ª
      • ±âŸ ³²¹Ì

Á¦6Àå °æÀï ±¸µµ

  • ±â¾÷ °³¿ä
    • Natus Medical Incorporated
    • Medtronic PLC
    • Integra Lifesciences Corporation
    • Compumedics
    • Nihon Kohden Corporation
    • Masimo Corporation
    • Advanced Brain Monitoring Inc.
    • Cadwell Industries Inc.
    • Koninklijke Philips NV
    • Nonin Medical Inc.
    • General Electric Company
    • Cerenion Oy

Á¦7Àå ½ÃÀå ±âȸ¿Í ÇâÈÄ µ¿Çâ

KSA 24.03.18

The Brain Monitoring Market size is estimated at USD 6.80 billion in 2024, and is expected to reach USD 9.25 billion by 2029, growing at a CAGR of 6.35% during the forecast period (2024-2029).

Brain Monitoring - Market

Key Highlights

  • The COVID-19 pandemic significantly impacted the healthcare system, including the brain-monitoring devices market. Neurological screenings were delayed or canceled due to the global lockdown, leading to reduced access to care for people with epilepsy and negative consequences for people with Parkinson's disease. However, as brain monitoring services resumed and COVID-19 cases decreased, the market is expected to recover from the pandemic's decline.
  • Several factors are driving the growth of the market, including aging demographics, the rising incidence of brain disorders, and the ease of device use and portability. For example, the population of Americans aged 65 and older is projected to grow from 58 million in 2021 to 88 million by 2050, with around 73% affected population aged 75 or older. Neurological diseases such as autism are prevalent worldwide, with World Health Organization (WHO) predicting that one in 100 children worldwide has autism. Thus, the increasing prevalence of brain disorders is expected to impact the growth of the brain monitoring market favorably.
  • Strategic activities such as product launches, mergers, and acquisitions are also expected to bolster market growth. For example, NeuroWave Systems Inc. received Food and Drug Administration (FDA) clearance for its NeuroSENSE NS-901 Monitor, a brain function monitor for assessing anesthesia and sedation adequacy in clinical settings. Brain Scientific received FDA clearance for Next-Gen NeuroCap EEG Headset, an advanced electroencephalography (EEG) electrode array used to obtain rapid EEGs in routine clinical and research settings.
  • Despite these factors, stringent regulations for device approval and a lack of skilled professionals are expected to restrain market growth. Overall, the brain monitoring devices market is expected to witness significant growth over the forecast period, driven by the increasing prevalence of brain disorders and product launches..

Brain Monitoring Market Trends

Electroencephalograph is Expected Witness a Healthy Growth Over the Forecast Period

  • The electroencephalography (EEG) machine is a device that captures the electrical activity of the brain through electrodes placed on a person's scalp. These electrodes record brain wave patterns, which are then transferred to a computer or cloud server for analysis. The use of EEG machines is becoming increasingly important in intensive care units (ICUs) as they allow for real-time monitoring of the cerebral activity of critically ill patients. The primary reason for obtaining an EEG in the ICU is to detect seizures in patients with and without acute brain injury.
  • Factors such as the increase in brain disorders and the growing adoption of EEG devices across different regions for the detection of brain issues are expected to drive market growth. For example, a survey conducted by the National Institute of Health in July 2022 across hospitals in the United States found that the use of an EEG device significantly improved electrographic seizure diagnosis by physicians. The sensitivity of electrographic seizure diagnosis increased from 77.8 to 100%, and the specificity improved from 63.9 to 89% compared to clinical diagnosis alone. This underscores the importance of EEG in the accurate diagnosis of seizures and its high adoption in intensive care units, fueling segment growth.
  • Moreover, advances in EEG devices are contributing significantly to the increasing demand for these devices. For instance, in March 2022, brain.space, an Israel-based company, developed a wireless EEG device that provides superior readings to traditional ones and can be set up without expert help. The cost-effectiveness and ease of use of this device are expected to attract significant attention in the coming years.
  • Additionally, in May 2021, Inspira Medical Centers Mullica Hill and Vineland, part of Inspira Health, launched the Ceribell Rapid Response EEG monitoring device. This ground-breaking technology helps identify and diagnose non-convulsive seizure activity in critically ill patients, ensuring that they receive the best care possible as soon as possible.
  • Therefore, due to the increasing adoption of EEG devices and the rise in product launches, the EEG machine segment is expected to witness significant growth over the forecast period.

North America Anticipated to Hold a Significant Market Share Over the Forecast Period

  • North America is poised to capture a significant share of the brain monitoring device market, driven by several factors. The region benefits from a well-established healthcare infrastructure, an increase in healthcare expenditure, and a rising aging population, which are key drivers of market growth. Additionally, continuous product launches by major players and a high incidence of brain disorders in the region are expected to have a positive impact on market growth.
  • For instance, according to a report by the Brain Injury Association of America published in March 2021, around 3.5 million Americans suffer from traumatic brain injuries annually. This report also revealed that out of the total injuries reported, approximately 2.8 million resulted in hospitalizations, and one in every 60 people suffers from traumatic brain injuries-related disability. As brain monitoring devices are essential for continuous monitoring and treatment of traumatic brain injuries, the increase in the incidence of these injuries is expected to boost demand for such devices.
  • Moreover, favorable reimbursement policies and increasing technological advancements, including the development of mobile EEG machines, real-time monitoring, and alerts, have also contributed to the market growth in the region. In May 2022, Philips received 510(k) clearance from the FDA for its new MR 7700 3.0T MR system, which allows radiologists to obtain six different clinically relevant nuclei across anatomies.
  • Additionally, in January 2022, the Cleveland Clinic launched a brain study aimed at diagnosing and preventing neurological diseases before symptoms occur. This new study collected data from up to 200,000 neurologically healthy individuals over 20 years to identify brain disease biomarkers and targets for preventing and curing neurological disorders.
  • In summary, the combination of an increase in brain disorders and the continuous launch of new products is expected to fuel significant growth in the brain monitoring device market in North America over the forecast period.

Brain Monitoring Industry Overview

The brain monitoring market is moderately competitive and comprises several significant and small industry players. At present, a few major players dominate the market in specific segments. However, mid-size to smaller companies are increasing their market presence by introducing new technologies with better usability and leveraging technological advancements and product innovations.

Medtronic PLC, Integra LifeSciences Corporation, Nihon Kohden Corporation, Masimo Corporation, and Natus Medical Incorporated are some of the companies that hold a substantial market share in the brain monitoring market.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Geriatric Population
    • 4.2.2 Rise in Incidences of Brain Disorders
    • 4.2.3 Technological Advancements in Brain Monitoring Devices
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulations for the Device Approval
    • 4.3.2 Lack of Skilled Personnel to Handle Devices
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product Type
    • 5.1.1 Magnetoencephalograph
    • 5.1.2 Electroencephalograph
    • 5.1.3 Cerebral Oximeters
    • 5.1.4 Functional Magnetic Resonance Imaging (fMRI)
    • 5.1.5 Intracranial Pressure Monitoring Devices
    • 5.1.6 Other Product Types
  • 5.2 By Application
    • 5.2.1 Parkinson's Disease
    • 5.2.2 Traumatic Brain Injury
    • 5.2.3 Epilepsy
    • 5.2.4 Dementia
    • 5.2.5 Sleep Disorders
    • 5.2.6 Other Applications
  • 5.3 By End User
    • 5.3.1 Hospitals
    • 5.3.2 Diagnostic Centers
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Natus Medical Incorporated
    • 6.1.2 Medtronic PLC
    • 6.1.3 Integra Lifesciences Corporation
    • 6.1.4 Compumedics
    • 6.1.5 Nihon Kohden Corporation
    • 6.1.6 Masimo Corporation
    • 6.1.7 Advanced Brain Monitoring Inc.
    • 6.1.8 Cadwell Industries Inc.
    • 6.1.9 Koninklijke Philips NV
    • 6.1.10 Nonin Medical Inc.
    • 6.1.11 General Electric Company
    • 6.1.12 Cerenion Oy

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦